Early-Stage Cell And Gene Therapy Progress: Updates From Casebia, BlueRock, Athersys, Cynata
Executive Summary
Scrip caught up with several companies during the recent Cell and Gene Meeting on the Mesa, sponsored by the Alliance for Regenerative Medicine.
You may also be interested in...
Finance Watch: Biopharma Fundraising Impact Expected, But Not Apparent Yet
While COVID-19 shocked global financial markets and is expected to impact biopharma fundraising, investment in drug developers continues, including through two new venture capital funds totaling nearly $2bn. Also, Coherus issues debt to fund deals and MOMA launches with $86m in VC cash.
Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
Cynata In Potential Japan Double As Fujifilm Acquires Lead Asset
Diversified Japanese giant gains global rights to Cynata’s novel therapy for GvHD as part of continued push into cell and regenerative medicine, amid ongoing discussions between Sumitomo Dainippon and the Australian bioventure over a potential wider acquisition.